Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.

[1]  S. Ferkal,et al.  Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  M. Haedersdal,et al.  Efficacy and safety of laser-assisted combination chemotherapy: A follow-up study of treatment with 5-fluorouracil and cisplatin for basal cell carcinoma. , 2021, Lasers in surgery and medicine.

[3]  S. Peltonen,et al.  Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience. , 2021, European journal of medical genetics.

[4]  J. Tonsgard,et al.  Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials , 2021, Neurology.

[5]  A. Stemmer-Rachamimov,et al.  Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas into Clinical Research. , 2021, Neurology.

[6]  R. R. Anderson,et al.  Validating Techniques for Measurement of Cutaneous Neurofibromas , 2021, Neurology.

[7]  C. Janfelt,et al.  Bleomycin administered by laser-assisted drug delivery or intradermal needle-injection results in distinct biodistribution patterns in skin: in vivo investigations with mass spectrometry imaging , 2021, Drug delivery.

[8]  A. Rubenstein,et al.  Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1 , 2021, Heliyon.

[9]  E. Olasz,et al.  Photodynamic Therapy for Benign Cutaneous Neurofibromas Using Aminolevulinic Acid Topical Application and 633 nm Red Light Illumination , 2021, Photobiomodulation, photomedicine, and laser surgery.

[10]  D. Gutmann,et al.  Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. , 2020, The Journal of clinical investigation.

[11]  M. Fijałkowska,et al.  Clinical picture and treatment of cutaneous lesions in patients with neurofibromatosis type 1 , 2020, Postepy dermatologii i alergologii.

[12]  S. Steinberg,et al.  Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.

[13]  P. Wolkenstein,et al.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966 , 2020, Orphanet journal of rare diseases.

[14]  L. Le,et al.  Management of cutaneous neurofibroma: current therapy and future directions , 2019, Neuro-oncology advances.

[15]  C. Pratilas,et al.  Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling , 2019, bioRxiv.

[16]  I. Blanco,et al.  Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey , 2019, Orphanet Journal of Rare Diseases.

[17]  L. Le,et al.  Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1. , 2019, JCI insight.

[18]  J. Slopis,et al.  Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial , 2018, Drugs in R&D.

[19]  Douglas C. Miller,et al.  Cutaneous neurofibromas , 2018, Neurology.

[20]  B. Korf,et al.  Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study , 2018, Orphanet Journal of Rare Diseases.

[21]  K. Kosaki,et al.  Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1 , 2018, The Journal of dermatology.

[22]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[23]  N. Kirkpatrick,et al.  The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[24]  D. Larouche,et al.  27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions , 2016, BioMed research international.

[25]  P. Wolkenstein,et al.  Treatment of Neurofibromas with a Carbon Dioxide Laser: A Retrospective Cross-Sectional Study of 106 Patients , 2015, Dermatology.

[26]  Michael Hay,et al.  Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.

[27]  Nae-Ho Lee,et al.  Radiofrequency Ablation and Excision of Multiple Cutaneous Lesions in Neurofibromatosis Type 1 , 2013, Archives of plastic surgery.

[28]  J. Slopis,et al.  Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex , 2012, Drugs in R&D.

[29]  P. Wolkenstein,et al.  Evolving Pattern with Age of Cutaneous Signs in Neurofibromatosis Type 1: A Cross-Sectional Study of 728 Patients , 2011, Dermatology.

[30]  N. Scuderi,et al.  The Megasession Technique for Excision of Multiple Neurofibromas , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[31]  H. Weinberg,et al.  Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[32]  N. Samy,et al.  Non-excision treatment of multiple cutaneous neurofibromas by laser photocoagulation , 2008, Lasers in Medical Science.

[33]  J. Nakayama,et al.  Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed–radio frequency in combination with topical application of vitamin D3 ointment , 2007, The Journal of dermatology.

[34]  G. Page,et al.  Impact of neurofibromatosis 1 on Quality of Life: A cross‐sectional study of 176 American cases , 2006, American journal of medical genetics. Part A.

[35]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[36]  S. Huson,et al.  Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales , 1988 .

[37]  D. Goulian,et al.  Neurofibromatosis—Distribution of Lesions and Surgical Treatment , 1982, Annals of plastic surgery.

[38]  G. Stagni,et al.  Skin microdialysis-based estimation of systemic bioavailability fraction. , 2012, Journal of pharmaceutical sciences.

[39]  A. Leplège,et al.  Visibility of neurofibromatosis 1 and psychiatric morbidity. , 2003, Archives of dermatology.

[40]  M. Fartasch,et al.  Microdialysis for the evaluation of penetration through the human skin barrier - a promising tool for future research? , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  J. Pailheret.  [Plastic surgery in benign cutaneous manifestations of von Recklinghausen's disease]. , 1990, Chirurgie; memoires de l'Academie de chirurgie.